In a win for the Clinton Foundation's goal of preventing 10,000 prescription drug-related deaths over 5 years, privately held kaléo agreed to sell its Evzio Auto-Injector to universities and other institutional buyers at the low federal price.
Sequenom is teaming up with Cypher Genomics to develop a noninvasive prenatal test using the company's advanced genome interpretation screening technology, eyeing a bigger share of an increasingly competitive market.
French in vitro diagnostics outfit bioMérieux and Astute Medical are teaming up to develop Astute's test for acute kidney injury, continuing the companies' recent diagnostics winning streak and helping them capitalize on a growing market.
Kite Pharma, contending with a slew of rivals in the newfangled field of immuno-oncology, has aligned itself with a pioneer in the field, teaming up with an Israeli university to work on treatments that train the body's own defenses on cancerous growth.
Medical supply company B. Braun will be selling the surgical adhesive TissuGlu from startup Cohera Medical in Germany, Spain and Portugal under a new deal. The product received an approvable letter from the FDA in early January. At that time, Cohera said it expected FDA approval within a few weeks, but it hasn't come through quite yet.
AbbVie selected Unilife as its drug delivery partner. AbbVie paid $5 million to enter into the development and supply agreement.
Myriad Genetics is teaming up with the Institut Pasteur for a research project to address the growing tuberculosis (TB) epidemic, continuing the company's diagnostics winning streak and expanding its global footprint.
India's Piramal Enterprises made official its intention to purchase Kentucky's Coldstream Laboratories, for $30.6 million, a move that will push the company further into the contract manufacturing of drug delivery components like sterile injectable products, lyophilized (freeze-dried) parenterals, and antibody drug conjugates.
Over the past 6 months the up-and-coming Zymeworks has leveraged its expertise in bispecific antibodies into expanded development pacts with two marquee Big Pharma partners. Later today, positioning itself for what it sees as a pivotal year, the biotech plans to announce another research deal with the prolific Big Biotech Celgene, which is inking one of its classic collaborations sweetened by an upfront payment, an equity stake and up to $164 million per project for a slate of programs that represent its biggest potential payoff yet.
In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.